enVVeno Medical Bilan de santé

Santé financière contrôle des critères 6/6

enVVeno Medical possède un total de capitaux propres de $47.4M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $50.4M et de $3.0M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$48.38m
Fonds propres	US$47.37m
Total du passif	US$3.02m
Total des actifs	US$50.39m

Mises à jour récentes de la santé financière

Here's Why We're Not Too Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation

Jun 26

Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

Mar 07

Recent updates

Here's Why We're Not Too Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation

Jun 26

Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

Mar 07

Will enVVeno Medical (NASDAQ:NVNO) Spend Its Cash Wisely?

Aug 14

Is enVVeno Medical (NASDAQ:NVNO) In A Good Position To Deliver On Growth Plans?

Apr 22

We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Dec 21

enVVeno Medical: Unique Exposure To Venous Treatment Domain

Sep 23

We're Hopeful That enVVeno Medical (NASDAQ:NVNO) Will Use Its Cash Wisely

Aug 23

enVVeno Medical reports Q2 results

Aug 03

We Think enVVeno Medical (NASDAQ:NVNO) Can Afford To Drive Business Growth

May 10

We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Jan 25

Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics

Sep 08

Hancock Jaffe Laboratories finance chief sheds interim tag

Dec 31

Hancock Jaffe approves 1:25 reverse stock split

Nov 27

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de NVNO ( $49.1M ) dépassent ses passifs à court terme ( $2.2M ).

Passif à long terme: Les actifs à court terme de NVNO ( $49.1M ) dépassent ses passifs à long terme ( $791.0K ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: NVNO est sans dette.

Réduire la dette: NVNO n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: NVNO dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: NVNO dispose d'une marge de trésorerie suffisante pour 2.8 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 21.6 % chaque année.

enVVeno Medical Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Here's Why We're Not Too Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation

Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

Will enVVeno Medical (NASDAQ:NVNO) Spend Its Cash Wisely?

Is enVVeno Medical (NASDAQ:NVNO) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

We're Hopeful That enVVeno Medical (NASDAQ:NVNO) Will Use Its Cash Wisely

Recent updates

enVVeno Medical Corporation, Annual General Meeting, Dec 18, 2024

Envveno Medical Successfully Initiates 6-Month Pre-Clinical Glp Study Evaluating Envve(R)

New major risk - Shareholder dilution

New minor risk - Share price stability

enVVeno Medical Corporation has filed a Follow-on Equity Offering.

No longer forecast to breakeven

Here's Why We're Not Too Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation

enVeno Medical Corporation Announces Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the VenoValve(R) Pivotal Trial

enVVeno Medical Corporation Announces New Interim Venous Ulcer Healing Data from the VenoValve®? Pivotal Trial to Be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting

enVVeno Medical Corporation Announces Additional Topline Efficacy Data from the VenoValve U.S. Pivotal Trial to Be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024

enVVeno Medical Corporation Appoints Andrew Cormack as Its Chief Commercial Officer

Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

enVVeno Medical Corporation Announces the Presentation of Positive Topline Efficacy Data Showing Significant Clinical Improvement from the Savve U.S. Pivotal Trial for the Venovalve

New minor risk - Share price stability

Forecast to breakeven in 2026

enVVeno Medical Corporation Presents Positive Preliminary Device Related Material Adverse Event Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium

enVVeno Medical Corporation, Annual General Meeting, Dec 05, 2023

New minor risk - Shareholder dilution

Price target decreased by 15% to US$20.40

enVVeno Medical Corporation Achieves Full Enrollment for VenoValve U.S. Pivotal Trial

Will enVVeno Medical (NASDAQ:NVNO) Spend Its Cash Wisely?

New major risk - Share price stability

Envveno Medical Corporation Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study

New minor risk - Share price stability

Is enVVeno Medical (NASDAQ:NVNO) In A Good Position To Deliver On Growth Plans?

Envveno Medical Promotes Hamed Alavi to Senior Vice President and Chief Technology Officer

We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Envveno Medical Corporation Presents Positive Long-Term, Three-Year Observational Data from A Cohort of Patients That Participated in the Previously Concluded Venovalve First-In-Human Clinical Tria

Insufficient new directors

enVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve U.S. Pivotal Study

enVVeno Medical Corporation, Annual General Meeting, Nov 30, 2022

Insufficient new directors

Insufficient new directors

enVVeno Medical: Unique Exposure To Venous Treatment Domain

We're Hopeful That enVVeno Medical (NASDAQ:NVNO) Will Use Its Cash Wisely

enVVeno Medical reports Q2 results

We Think enVVeno Medical (NASDAQ:NVNO) Can Afford To Drive Business Growth

Price target decreased to US$24.00

No longer forecast to breakeven

We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Hancock Jaffe Laboratories, Inc Begins Enrollment for the U.S. Pivotal Trial for the Venovalve, Potential Treatment for Deep Venous Chronic Venous Insufficiency

Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics

Price target decreased to US$26.00

Forecast to breakeven in 2024

New 90-day low: US$7.37

Price target lowered to US$28.00

Hancock Jaffe Laboratories, Inc. has completed a Composite Units Offering in the amount of $35.999992 million.

Hancock Jaffe Laboratories, Inc. Appoints Craig Glynn Chief Financial Officer

Hancock Jaffe Laboratories finance chief sheds interim tag

Hancock Jaffe Receives Formal Notification from the Nasdaq Hearings Panel

Hancock Jaffe approves 1:25 reverse stock split

Hancock Jaffe Laboratories, Inc. announced delayed 10-Q filing

Hancock Jaffe Laboratories, Inc., Annual General Meeting, Dec 17, 2020

Hancock Jaffe Laboratories, Inc. (NasdaqCM:HJLI) entered into non-binding letter of intent to acquire Catheter Precision, Inc.

New 90-day high - US$0.56

New 90-day low - US$0.31

Hancock Jaffe Regains Compliance with Nasdaq Stockholder's Equity Rule

New 90-day low - US$0.31

Hancock Jaffe Laboratories, Inc. announced that it has received $1.556 million in funding

Hancock Jaffe Laboratories, Inc. has completed a Composite Units Offering in the amount of $4 million.

Hancock Jaffe Laboratories, Inc. announced that it expects to receive $1.556 million in funding

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines